Sugi Predict

Sugi Predict / Compounds / Tanogitran

Tanogitran

Tanogitran

SCHEMBL2471738

Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc([C@@](C)(NCC(=O)O)C(=O)N3CCCC3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 18/20 1.00
▸ F10 P00742 6/20 1.00
▸ PRSS1 P07477 2/20 0.61
▸ PRSS2 P07478 2/20 0.61
▸ PRSS3 P35030 2/20 0.61
▸ PLG P00747 3/20 0.52
▸ KLK1 P06870 1/20 0.52
▸ KLK5 Q9Y337 1/20 0.52
▸ SLC22A2 O15244 1/20 0.51
▸ PLAT P00750 1/20 0.51
▸ PROC P04070 1/20 0.51
▸ HPN P05981 1/20 0.51
▸ NQO2 P16083 1/20 0.51
▸ SLC47A2 Q86VL8 1/20 0.51
▸ SLC47A1 Q96FL8 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tanogitran SCHEMBL2989514 1.00 F2 (1.00) F2F10PRSS1PRSS2PRSS3
Tanogitran SCHEMBL29456575 1.00 F2 (1.00) F2F10PRSS1PRSS2PRSS3
Tanogitran SCHEMBL4445262 0.99 F2 (0.98) F2F10PRSS1PRSS2PRSS3
Tanogitran SCHEMBL7417719 0.99 F2 (0.98) F2F10PRSS1PRSS2PRSS3
Tanogitran SCHEMBL4937696 0.99 F2 (0.98) F2F10PRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL7413108 0.98 F2 (0.97) F2F10PRSS1PRSS2PRSS3
SCHEMBL4450206 0.93 F2 (0.87) F2F10PRSS1PRSS2PRSS3
SCHEMBL14260382 0.93 F2 (0.87) F2F10PRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL7414667 0.92 F2 (0.86) F2F10PRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL7411878 0.92 F2 (0.86) F2F10PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases EISERT WOLFGANG 2009-03-19 — — US claimed
US-20090022686-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-01-22 — — US claimed
US-7294721-B2 (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-11-13 — — US claimed
EP-1517687-B1 MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME BOEHRINGER INGELHEIM PHARMA (DE) 2007-06-20 — — EP claimed
US-20070099974-A1 (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition LINZ GUENTER 2007-05-03 — — US claimed
US-7169934-B2 (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-30 — — US claimed
EP-1529035-A1 CRYSTALLINE (R)-2-(4-AMIDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(CARBOXYMETHYLAMINO)-1(PYRROLIDINOCARBONYL)-ETHYL)-BENZIMIDAZOLE, AND THE USE THEREOF AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-11 — — EP claimed
US-20040023975-A1 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-02-05 — — US claimed
US-20040010026-A1 (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-15 — — US claimed
WO-2004000818-A1 CRYSTALLINE (R)-2-(4-AMIDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(CARBOXYMETHYLAMINO)-1(PYRROLIDINOCARBONYL)-ETHYL)-BENZIMIDAZOLE, AND THE USE THEREOF AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 — — WO claimed
EP-1095025-B1 BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2002-12-11 — — EP claimed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 — — US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 — — US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 — — US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 — — US disclosed
US-20040010026-A1 (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-15 — — US disclosed
WO-2004000310-A1 MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 — — WO disclosed
WO-2004000818-A1 CRYSTALLINE (R)-2-(4-AMIDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(CARBOXYMETHYLAMINO)-1(PYRROLIDINOCARBONYL)-ETHYL)-BENZIMIDAZOLE, AND THE USE THEREOF AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 — — WO disclosed
WO-2004000818-A1 CRYSTALLINE (R)-2-(4-AMIDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(CARBOXYMETHYLAMINO)-1(PYRROLIDINOCARBONYL)-ETHYL)-BENZIMIDAZOLE, AND THE USE THEREOF AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 — — WO disclosed
WO-2004000818-A1 CRYSTALLINE (R)-2-(4-AMIDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(CARBOXYMETHYLAMINO)-1(PYRROLIDINOCARBONYL)-ETHYL)-BENZIMIDAZOLE, AND THE USE THEREOF AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023975-A1 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome IL5, TSLP, TLR5 F2 214/4885F10 1136/4885PRSS1 161/4885
US-20070099974-A1 (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition PBRM1, PKD1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 F2 1325/4885F10 3617/4885PRSS1 3896/4885
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L F2 30/4885F10 360/4885PRSS1 3275/4885
US-20090022686-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME IL5, TSLP, TLR5 F2 214/4885F10 1136/4885PRSS1 161/4885
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases PEPD, PLAT, TFPI F2 8/4885F10 51/4885PRSS1 109/4885
US-20040010026-A1 (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition PBRM1, H1-4, PKD1 F2 1545/4885F10 3756/4885PRSS1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.